



Published by
The Federation of Medical Societies of Hong Kong
 4/F Duke of Windsor Social Service Building
 15 Hennessy Road, Wanchai, Hong Kong
 Tel: 2527 8898 Fax: 2865 0345
 Homepage: www.fmshk.com.hk Email: info@fmshk.com.hk

EDITOR-IN-CHIEF

Dr. KING Wing-keung, Walter 金永強醫生

EDITORS

Dr. CHAN Chi-fung, Godfrey
 陳志峰醫生 (Paediatrics)
 Dr. CHAN Chun-hon, Edmond
 陳振漢醫生 (General Practice)
 Dr. MOK Chun-on
 莫鎮安醫生 (Plastic Surgery)
 Dr. WU Young-yuen, Adrian
 鄺揚源醫生 (Immunology & Allergy)

EDITORIAL BOARD

Dr. AU-YEUNG Cheuk-lun, Henry
 區陽卓倫醫生 (Paediatrics)
 Dr. CHAN Chi-wai, Angus
 陳志偉醫生 (General Surgery)
 Dr. Norman CHAN
 陳諾醫生 (Diabetes, Endocrinology & Metabolism)
 Dr. CHIANG Chung-seung
 蔣志想醫生 (Cardiology)
 Dr. CHONG Lai-yin
 莊禮賢醫生 (Dermatology & Venereology)
 Dr. CHUH An-tung, Antonio
 許晏冬醫生 (Family Medicine)
 Dr. FAN Yiu-wah
 范耀華醫生 (Neurosurgery)
 Dr. FONG Ka-yeung
 方嘉揚醫生 (Neurology)
 Dr. FUNG Ho-chuen, Alec
 馮浩泉醫生 (Dermatology & Venereology)
 Dr. FUNG Yee-ping, Adrian
 馮貽邦醫生 (Dermatology & Venereology)
 Dr. HOP Pak-leung
 何栢良醫生 (Clinical Microbiology and Infections)
 Dr. KWOK Kwan-ho, Alvin
 郭坤豪醫生 (Ophthalmology)
 Dr. KWOK Po-yin, Samuel
 郭寶賢醫生 (General Surgery)
 Dr. LAI Cheuk Seen, Edward
 黎卓先醫生 (General Surgery)
 Dr. LAI Kei-wai, Christopher
 賴奇偉醫生 (Respiratory Medicine)
 Dr. LAI Sik-to, Thomas
 黎錫滔醫生 (Gastroenterology & Hepatology)
 Dr. LAM Wai-man, Wendy
 林慧文醫生 (Radiology)
 Dr. LAO Tzu-his, Terence
 勞子信醫生 (Obstetrics & Gynaecology)
 Dr. LEE Man-piu, Albert
 李文彪醫生 (Dentistry)
 Dr. LEUNG Wai-tong, Thomas
 梁惠棠醫生 (Clinical Oncology)
 Dr. LO See-kit, Raymond
 勞思傑醫生 (Geriatrics)
 Dr. MAN Chi-wai
 文志衛醫生 (Urology)
 Dr. MOK Mo-yin
 莫慕賢醫生 (Rheumatology)
 Dr. MONG Hoi-Keung
 蒙海強醫生 (Forensic Pathology)
 Dr. TEO Man-lung, Peter
 張文龍醫生 (Clinical Oncology)
 Dr. TSANG Wai-kay
 曾偉基醫生 (Nephrology)
 Dr. TSE Tak-fu
 謝德富醫生 (Cardiology)
 Dr. WU Wing-cheung, Stephen
 胡永祥醫生 (Orthopaedics & Traumatology)

BOARD OF BUSINESS CONSULTANTS

Dr. LO Kwong-yin, Richard
 羅光彥醫生 (Urology)
 Dr. LOW Chung-kai, Louis
 盧忠啟醫生 (Paediatrics)

PROJECT MANAGER

Ms. CHENG Shu-yue, Sue 鄭淑儀 小姐

Printed and designed by **New Century**
 Printing Industrial Limited

Epilepsy editorial

Dr. Jason KY Fong

FRCP(E), FHKAM (Medicine)

Private Neurologist

Editor



Dr. Jason KY Fong

Epilepsy affects about 0.5-1% of our population and is one of the commonest neurological disorders worldwide. The underlying etiology is diverse and the clinical manifestations are often variable. Patients with chronic epilepsy should be managed or reviewed regularly by specialists to optimise seizure control and minimize possible side-effects. Although patients who develop their first attack of seizure could be the initial manifestation of epilepsy, this may also be the presentation of a serious acute illness e.g. stroke, viral encephalitis, hypoglycaemia. They should therefore receive fast track evaluation or hospitalised to speed up the diagnostic process. A summary of this initial management is provided in the article on "Management of First Epileptic Seizure", to which the front-line medical staff may find useful.

Multiple data need to be gathered when initiating a treatment plan for a person with epilepsy. Patient factors (e.g. female, elderly, children), disease factors (e.g. underlying brain lesion, encephalitis, genetic or metabolic disorders), and co-morbidities (e.g. mental retardation, depression, liver or renal disease) deserve careful and individual considerations. In this monthly symposium on epilepsy, Dr. Gardian Fong has provided a concise summary for treatment of epilepsy in women (patient factor) and Dr. Fan Yiu-wah has illustrated how brain tumour (the disease factor) will affect the management of epilepsy. Epilepsy associated with brain tumour (i.e. lesional epilepsy) is likely to be drug resistant and the optimal AED treatment in this category of patients remains undetermined. Dr. Fan has highlighted the importance of interaction with chemotherapeutic agents. For this reason, the newer AED with little drug interaction (e.g. gabapentin, levetiracetam, pregabalin) may become the drug of choice. Finally, AED is generally not indicated in patients with only brain tumours and without epilepsy.

There is no doubt that the mainstay of epilepsy is antiepileptic drug (AED) treatment. A number of new drugs have added into our armamentarium in the past decade (e.g. ox-carbamazepine, lamotrigene, levetiracetam, topiramate) although some others are losing popularity. One has to be cautious about any new AED as some serious side-effects may only become apparent years after marketing. This can be exemplified by the visual field constriction and aplastic anaemia attributed to vigabatrin and felbamate respectively. In the drug monograph section, Dr. Patrick Kwan provides us a timely review on the new drug, pregabalin, which is structurally similar to gabapentin but with a much higher potency. In addition, other co-advantages (anti-anxiety, sleep enhancement) render this drug even more promising during add-on therapy for intractable epilepsy.

I hope we are going to have the second symposium dedicated to epilepsy in the future covering the other aspects of treatments (e.g. cognitive aspects, psychosocial and psychiatric issues, learning disabilities). These are important and often neglected areas in the management of chronic epilepsy.